



MOLECULAR. IN MINUTES.™

ID NOW™ RAPID MOLECULAR TESTING

TRUSTED RESULTS DURING THE PATIENT ENCOUNTER

The ID NOW™ Platform provides highly sensitive test results in as few as **2–13 minutes**¹

- **Fastest molecular** platform for infectious diseases²
- More sensitive than rapid antigen tests to **improve diagnostic accuracy**³⁻⁶
- Created for point-of-care **operational speed, clinical utility and timely patient care**
- CLIA-waived **intuitive procedure** allows for easy standardization across care settings
- **Bi-directional** connectivity and **remote upgrade** capability

ID NOW™ RESPIRATORY ASSAY MENU

COVID-19
6–12 mins

Influenza A & B
5–13 mins⁷

Strep A
2–6 mins¹

RSV
≤ 13 mins



RAPID AND ACTIONABLE

RESULTS DURING THE PATIENT ENCOUNTER


The ID NOW™ Platform provides reliable real-time molecular test results in minutes to speed operations and optimize clinical utility in time-sensitive patient care settings.



UNCOMPROMISED MOLECULAR PERFORMANCE

INCREASE SENSITIVITY

Compared to antigen tests, molecular amplification generates billions of copies of the targeted genetic material to increase detection of even low-level infections.



INCREASE SPEED

The ID NOW™ Platform amplifies the sample using advanced proprietary isothermal technology to eliminate lengthy PCR temperature cycling and reduce isothermal processes for more timely and informed clinical decision-making.

| ID NOW™ FASTEST AVAILABLE | | | | |
|------------------------------|----------------------------------|---|---|--|
| Amplification Technology | PCR Polymerase Chain Reaction | NEAR Nicking Enzyme Amplification Reaction | HDA Helicase-dependent Amplification | LAMP Loop-mediated Isothermal Amplification |
| Amplification | Thermocycling | Isothermal | Isothermal | Isothermal |
| Initial Amplification Step | Heat Cycles | Enzymes | Enzymes | Enzymes |
| Requires Temp Changes | Yes | No | No | No |
| TIME TO RESULTS² | 15 mins–2+ hrs | 2–13 mins | ≥35 mins | ≥60 mins |

FLEXIBLE AND EFFICIENT

TESTING TO STREAMLINE CLINICAL WORKFLOW AND PATIENT CARE



Easily test based on clinical assessment and fluctuations in respiratory illnesses to optimize pretest probability



Align with diagnostic stewardship initiatives by delivering the right test, at the right time, to prompt the right action

SIMPLE AND SMART TECHNOLOGY

DESIGNED FOR ALL POINTS OF CARE



- Minimal training with on-screen video-guided operation
- Automated visually-displayed results to eliminate subjective test interpretation
- No complex sample handling or manual pipetting required
- POC Link connectivity tool to enable streamlined remote software updates and accelerated troubleshooting for ID NOW™ Instruments



The ID NOW™ Platform supports Ethernet® and WiFi® connections to POC Link



POC Link meets industry cybersecurity standards and data privacy requirements



No protected health information (PHI), personally identifiable information (PII) or other sensitive information is collected by POC Link.

For in vitro Diagnostic Use Only

With COVID-19 + Flu Add-on Sequential Workflow*

| PRODUCT NAME | PRODUCT CODE | CPT® CODE [†] | MEDICARE RATE ^{††} | CPT® CODE [†] | MEDICARE RATE ^{††} |
|------------------------------------|--------------|------------------------|-----------------------------|------------------------|-----------------------------|
| ID NOW™ INSTRUMENT | NAT-024 | | | | |
| ID NOW™ COVID-19 2.0 TEST KIT | 192-000 | 87635 | \$51.31 | 87636 | \$142.63 |
| ID NOW™ INFLUENZA A & B 2 TEST KIT | 427-000 | 87502 | \$95.80 | | |
| ID NOW™ RSV TEST KIT | 435-000 | 87634 | \$70.20 | | |
| ID NOW™ STREP A 2 TEST KIT | 734-000 | 87651 | \$35.09 | | |

Each test kit contains 24 tests, collection swabs and controls. Separate controls are available for each test.

*Sequential workflow: Run the ID NOW™ COVID-19 2.0 followed by the ID NOW™ Influenza A & B 2 (each test sold separately). ID NOW™ software update to version 7.1 required.



CONTACT YOUR LOCAL ABBOTT REPRESENTATIVE
OR VISIT GLOBALPOINTOFCARE.ABBOTT

[†]Providers with a CLIA Certificate of Waiver should use the QW modifier when appropriate.

^{††}2025 Medicare Clinical Laboratory Fee Schedule.

Current Procedural Terminology (CPT®) code information and current Medicare allowable reimbursement rates available at www.codemap.com/abbottpoc. As a courtesy to its customers, Abbott is pleased to provide relevant coding and payment information that is current as of the date of publication of this piece (February 2025), but which may be subject to change at any time. Abbott does not assume any obligation to notify customers of any changes to the coding or payment information included in this piece. In addition, various payers may provide specific billing instructions for reporting these tests that may differ from or include requirements not presented here. The customer is ultimately responsible for determining the appropriate codes, coverage, and payment policies for actual testing services performed for individual patients. Abbott does not guarantee third party coverage of payment for our products or reimburse customers for claims that are denied by third party payors.

1. Abbott. ID NOW™ Strep A 2 Clinical Trial Data on File. 2. Abbott. ID NOW™ Rapid Test Times to Result Analysis (v2.0). 3. Fragkou PC, Moschopoulos CD, Dimopoulou D, et al; European Society of Clinical Microbiology and Infection Study Group for Respiratory Viruses. Performance of point-of care molecular and antigen-based tests for SARS-CoV-2: a living systematic review and meta-analysis. *Clin Microbiol Infect.* 2023;29(3):291-301. doi:10.1016/j.cmi.2022.10.028 4. Merckx J, Wali R, Schiller I, et al. Diagnostic accuracy of novel and traditional rapid tests for influenza infection compared with reverse transcriptase polymerase chain reaction: a systematic review and meta-analysis. *Ann Intern Med.* 2017;167(6):394-409. doi:10.7326/M17-0848 5. Cohen JF, Bertille N, Cohen R, Chalumeau M. Rapid antigen detection test for group A streptococcus in children with pharyngitis. *Cochrane Database Syst Rev.* 2016;7(7):CD010502. doi:10.1002/14651858.CD010502.pub2 6. Bernstein DI, Mejias A, Rath B, Woods CW, Deeter JP. Summarizing study characteristics and diagnostic performance of commercially available tests for respiratory syncytial virus: a scoping literature review in the COVID-19 era. *J Appl Lab Med.* 2022;8(2):353-371. 7. Abbott. ID NOW™ Influenza A & B 2 Clinical Trial Data on File.

© 2025 Abbott. All rights reserved. All trademarks referenced are trademarks of either the Abbott group of companies or their respective owners. CPT is a registered trademark of the American Medical Association. Any photos displayed are for illustrative purposes only. RDX-24001075-06 02/25

